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Abstract
Background: Incomplete drug regimen compliance (DRC) and white-coat hypertension are two of
several possible causes of uncontrolled hypertension. Therefore the aim of the present study was to
compare DRC in hypertensives treated with combination therapy whose blood pressures (BP) were
controlled vers. uncontrolled after 4 weeks of self-monitored BP measurement. To observe the
consequences in uncontrolled patients of switching one drug of the combination therapy to candesartan/
HCTZ (16 mg/12.5 mg) with and without a compliance intervention program.
Methods:  Self-and ambulatory-monitoring of BP were done with upper arm oscillometric devices.
Patients' dosing histories were compiled electronically (MEMS(c), AARDEX). Patients with office blood
pressure (OBP) >140/90 mmHg despite combination therapy were begun on MEMS monitoring and self
BP measurement for 4 weeks of run-in. Of 62 such patients, 18 (29%) patients were normotensive
according to self BP measurement and ambulatory BP measurement at 4 weeks (Group A); in the
remaining 44 still uncontrolled patients, candesartan/HCTZ was substituted for one of the combination
therapy drugs, with half these patients receiving passive compliance monitoring (B) and half a DRC
intervention program (C). All groups were then followed for 8 weeks.
Results: DRC before week 4 was significantly higher in A than in the uncontrolled patients (B&C). DRC
was stable during run-in A, but declined in B and C. DRC after week 4 was not different in the three groups
and stayed constant over time. DRC during weekends was lower than during weekdays in all groups.
In group A no significant change in blood pressure was observed with all three methods of BP
measurements. In groups B and C significant reductions of systolic and diastolic BP were observed for
ABPM and SBPM. After the change to candesartan/HCTZ in B&C ambulatory 24-h-BP (ABPM) was
normalized in 39% of patients.
Conclusion: Normalization of BP was associated with superior drug regimen compliance in previously
uncontrolled patients treated with a combination drug regimen. Switching still-uncontrolled patients to
candesartan/HCTZ significantly improved BP control and stabilized a declining DRC.
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Background
Understanding and optimizing the management of hyper-
tension is complicated by the lability of blood pressure,
the sources of which include (a) white-coat effects, (b)
variable exposure to prescribed antihypertensive drug(s),
created by patients' variable but infrequently measured
compliance with prescribed dosing regimen(s), (c) differ-
ent magnitudes and time-courses of action of the many
antihypertensive drugs, each of which has its own charac-
teristic pharmacokinetic and pharmacodynamic behavior,
(d) diurnal fluctuations in blood pressure, which may
exceed in magnitude the hypotensive effects of antihyper-
tensive drugs.
A further disappointing finding has been pharmaco-epi-
demiologic data showing a high proportion of treated
patients who discontinue treatment for no clear reason
within some months or a year or two after the start of
treatment [1,2]. This problem being called 'short persist-
ence' in the pharmaco-epidemiologic literature. Thus, we
have the twin problems of too few patients effectively
treated for too short a time.
Candesartan cilexitil (Candesartan) is a highly selective
and long acting AT1 receptor blocker with excellent
blood-pressure lowering efficacy and a prolonged dura-
tion of antihypertensive efficacy exceeding 24 hours. In a
"missed dose" study by Lacourcière and Asmar the dura-
tion of action of candesartan suggested that this AT1
receptor blocker may provide added confidence of thera-
peutic coverage in many patients who may not be 100%
compliant with their once-daily medication regimen [3].
The realization of such pharmaceuticals has, however, not
solved either the compliance or the persistence problems
[4]. We have good tools, but poor methods for applying
them in long-running programs of patient management.
Against that background, the present study was designed
as a pilot study in a group of longtime treatment-resistant
hypertensives, to explore some aspects of the respective
roles of poor compliance with prescribed drug regimens,
persistent unresponsiveness to correctly administered
drug, and several modest interventions – a change in one
of the prescribed drugs, use of ambulatory blood pressure
monitoring, informing patients that their dosing histories
were being continuously compiled, and some feedback to
patients of both blood pressure data and dosing history
data.
Methods
Figure 1 outlines the design of the study. Patients with
essential hypertension and office blood pressure (OBP) ≥
140/90 mmHg, despite combination therapy (> 2 antihy-
pertensive drugs), were monitored by MEMS (Medication
event monitoring system, Aardex company Switzerland)
and by self-measurement of blood pressure (SBPM) dur-
ing a 4 week period. In patients with elevated SBPM and
24-h ambulatory blood pressure (ABPM) after the run-in
period, one drug of the hypertensive regimen was substi-
tuted by candesartan/hydrochlorthiazide (16/12.5 mg).
Patients with normotension after run-in were judged to
have a white-coat effect, and were assigned to group A as
a comparison-group for the remainder of the patients,
who were persistently hypertensive and were randomized
to groups B or C. Group C received a structured hyperten-
sion teaching program [5] and interactive MEMS Monitor
with a visiual reminder of the number of drugs taken and
the time intreval elapsed since the last drug intake. We
used an informal, shortened teaching program (30 min.),
which included the following items and was always per-
formed by the same investigator (S.U.)
a. Definition of normal values for office, SBPM and ABPM
and target BPs
b. Prognostic implication of uncontrolled hypertension
c. Effect of non-compliance on control rate
d. Correct use of SBPM
In contrast, Group B was managed in the usual manner,
with dosing history data being compiled by a standard,
non-interactive MEMS Monitor, but without any special
effort being made to improve the patients' compliance.
Patients were consecutively recruited from the outpatient
department of the Medizinische Poliklinik. Patients were
refered to our department by GPs for resistant or difficult
to treat hypertension. All patients gave informed consent
to participate in the study and were informed about the
function of the MEMS system. The University of Bonn
issued a positive ethical vote on the study.
MEMS system
Candersartan was dispensed in Medication Event Moni-
toring System (MEMS®, AARDEX Ltd.) containers. The
MEMS system comprises an electronic pill-bottle cap
embedding a microship that creates an electronic time-
stamp upon opening and closing the bottle. These time-
stamps comprise a complete dosage history. Mems caps
may also include a LCD display that reminds the patient
the number of pills taken since the beginning of the day.
In this article, the term interactive MEMS refers to the
devices with screen displays. The recorded data can then
be downloaded to a personal computer using Powerview
software (Aardex Ltd.). This software offers features to vis-
ualise and compute basic individual statistics. Adherence
to Candersartan was assessed using MEMS devices overBMC Cardiovascular Disorders 2006, 6:36 http://www.biomedcentral.com/1471-2261/6/36
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the course of the study. Both interactive and non-interac-
tive devices were used depending on the intervention
group.
The quality of execution of the prescribed drug regimen is
called 'compliance', defined as 'the extent to which the
patient's dosing history corresponds to the prescribed reg-
imen' (Fig. 2). The length of time between onset and dis-
continuation of execution is called 'persistence'. The
general term, 'adherence' subsumes acceptance, execu-
tion, and discontinuation. 'Poor adherence signals that
something is or was wrong with the drug regimen – not
accepted, or badly executed and/or discontinued prema-
turely. In this context, compliance will be measured by the
percentage of days with correct intake (cod) and the per-
centage of prescribed number of doses taken (tac).
Blood pressure monitoring
Self measurement was performed with a validated, oscil-
lometric upper arm device, A&D UA-767 [7], After suffi-
cient training in the correct method of blood pressure
measurement, duplicate measurements were performed
between 6–9 AM (before medication) and 6–9 PM for at
least three days/week for the whole study period. Data
were stored electronically and were downloaded to a PC
at the end of the study.
Ambulatory 24-h BP measurement was done with the
"CardioTens-01" (Meditech, Budapest, Hungary) device
[6], which measured blood pressure oscillometrically
every 15 minutes in the period between 10.00 a.m. and
10.00 p.m., every 30 minutes between 10.00 p.m. and
06.00 a.m. and once every 10 minutes between 06.00 a.m.
and 10.00 a.m. This method of blood pressure monitor-
ing has been validated in accordance with the protocol of
the British Hypertension Society.
The definitions of controlled hypertension are: self-meas-
urement <135/85 mmHg, office <140/90 mmHg, ABPM
(whole 24 h period) <130/80 mmHg. We decided to work
on ABPM since this technique has important prognostic
value, especially in patients with refractory hypertension
[8]. Patients with discrepant results of ABPM and SBPM at
week 4 were excluded from the analysis (2 patients).
Statistical methods
The non-parametric Wilcoxon test was used to compare
adherence distribution between groups. Comparison of
binary time series were realized using a logistic regression
where dependence among observations from a same
patient over time was taken into account through a condi-
tional approach. Comparisons of BP values were per-
formed with the t-test for comparison between baseline
Design of the study Figure 1
Design of the study.
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and week 12. All significance tests are two-sided and sta-
tistical significance is set at 5%. All analyses are performed
using the S-plus® version 6.2. BP values are expressed as
means+S.D. In case of multiple comparisons between
groups, a Bonferroni's correction of the significance level
has been applied.
Sample size was calculated to detect a 5 mmHg difference
in systolic ABPM at 90% power and p < 0.05 in 20
patients.
Results
Sixty-two patients with essential hypertension and OBP ≥
140/90 mmHg, despite combination therapy, were
enrolled (26 female and 36 male, age 61+9 years). After 4
weeks of run-in, 18 of these (29%) were normotensive at
4 weeks, and, on that basis, were designated Group A. For
the remaining 44 evaluable, still-uncontrolled patients,
candesartan/hydrochlorothiazide was substituted at week
4 for one of the previously prescribed combination ther-
apy drugs. The choice of drug was left to the discretion of
a experienced hypertension specialist. These 44 patients
were randomized between group B (n = 20), to continue
receiving passive compliance monitoring, and Group C (n
= 24), to receive an intervention program designed to
improve drug regimen compliance. Group B had 20 eval-
uable patients and C had 24. All groups were then fol-
lowed for 8 weeks. The characteristics of patients with
different antihypertensive drugs used at the beginning of
the study are presented in table 1. There were no signifi-
cant differences between groups B and C. Patients of
group B and C had more diabetes than patients of group
A. The classes of antihypertensive drugs which were
replaced by candesartan/HCTZ in groups B and C patients
after the run-in period are given in table 2.
Compliance
Summarizing the history in an overall measure
We consider simple statistics to summarize the patient's
compliance history. The statistics used in this context are
the percentage of days with correct intake (cod) and the
percentage of prescribed number of doses taken (tac).
Those quantities were computed for each patient during
the two phases of the study. Table 3 summarizes the dif-
ferent compliance statistics during the two phases in the
different groups. Using a Wilcoxon test to compare com-
pliance statistics between the randomized groups, none of
the measures discussed shows a significant difference
Formal definition of adherence/compliance/persistence Figure 2
Formal definition of adherence/compliance/persistence.
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between randomized groups at the nominal 5% level.
Although the measures provide a well-understood, simple
description, patient compliance can vary in many differ-
ent ways over time. Summarizing the history in just a few
measures may lose power to detect relevant differences in
compliance patterns. The next logical step is to capture the
temporal evolution of the daily compliance. The next sec-
tions describe relevant methodology.
Analysing adherence over time before week 4
The aim of this section is to describe the evolution of an
informative measure of adherence in randomized treat-
ment groups. Because adherence to prescribed therapy
measures the extent to which a person's behavior coin-
cides with medical advice, it covers both a behavior and a
measure. One factor influencing the other delivers raw
data that have a complex structure with unusual correla-
tion patterns of dosing intervals, and it is not obvious how
to analyze these patterns. Rather than study detailed pat-
terns, we summarize the adherence pattern in a sequence
of binary data Zij indicating whether yes (1) or no (0), at
least the prescribed number of doses were taken on day j
by patient i. This coding retains much of the temporal
structure in the individual patterns, but not exact times of
drug doses [9]. The observed proportion of good adherers
on each separate day before week 4 visit, i.e., patients hav-
ing taken at least their prescribed number of doses, is pre-
sented in Figure 3. The adherence in group BC has been
found significantly lower than in group A (p < 0.001).
Finally the model has confirmed a significant decrease of
adherence over time in group BC (p = 0.012).
Analysing compliance over time after week 4
The observed proportion of good compliers on each sep-
arate day after week 4 visit is presented in Figure 4. The
resulting model did not highlight any significant differ-
ences between the three groups. A significant decrease
over time could not be identified. Interestingly, it showed
the existence of a weekend effect leading to a lower daily
probability of intake during the weekend defined as Fri-
day, Saturday and Sunday. The odds ratio of taking a dose
the weekend (Friday – Sunday) compared to the odds of
taking the rest of the week was 50.1 % (95% confidence
interval : [28.1–90.0]).
OBP, SBPM and ABPM blood pressure control
Table 4 shows the blood pressure values for all three
methods of measurement after the run-in period (visit
week 4).
The change in blood pressure between visit week 4 and
visit week 12 is shown in the figure 5.
For SBPM the mean values 14 days preceding week 4 visit
are compared with the 14 days preceding week 12 visit are
compared. For ABPM the respective values of the last day
of run-in and the last day of week 12 are compared. As
expected in group A with unchanged medication no sig-
nificant change in blood pressure was observed with all
three methods. In groups B and C significant reductions of
systolic and diastolic BP were observed for SBPM and
ABPM.
The blood pressure lowering effect of substitution by Can-
desartan/HCT was most pronounced as assessed by systo-
lic OBPM (162 ± 15 vs 148 ± 17 for group B and 161 ± 16
vs 142 ± 23 for group C; p < 0.025) whereas diastolic
OBPM reduction did not change significantly.
The BP lowering effect resulted in normlization of ABPM
in 39 % of patients in group B and 39% of patients in
groups C. The confounding created by white-coat effect is
illustrated by the data from Group A: at week 12, 80%
were uncontrolled by OBP, whereas only 17% were
uncontrolled as assessed by ABPM.
At the end of the study 53% of all patients included
(group A, B, and C) had normal ABPM values, i.e. <130/
80 mmHg for the whole 24-h period.
Table 2: Classes of antihypertensive drugs replaced by 
candesartan/HCT after run-in period
Groups B C
Diuretics 10 11
ACE-inhibitor 5 6
Calcium channel Blocker 2 2
Angiotensin Receptor Blocker 3 4
Alfa 1-Receptor-blocker 0 1
Table 1: Baseline characteristics of patients
Groups A B C
Age (y) 58 ± 10 60 ± 10 64 ± 6
Sex (male) 9 14 14
Height (cm) 169 ± 8 172 ± 9 170 ± 8
Weight (kg) 78 ± 12 85 ± 14 79 ± 15
BMI (kg/m2) 27 ± 3.2 29 ± 4.1 27 ± 3.7
Coronay heart disease 7 12 10
Myocardial infarction 3 3 2
Diabetes 0 10 8
Smoking 4 0 4
Dyslipidemia 12 10 15
Beta-blocker 13 11 16
Diuretics 13 15 13
Calcium channel blocker 6 10 11
ACE-inhibitor 13 11 17
Alpha 1-Receptor-blocker 0 5 3
Angiotensin Receptor Blocker 3 3 4BMC Cardiovascular Disorders 2006, 6:36 http://www.biomedcentral.com/1471-2261/6/36
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Number of antihypertensive drugs
The average number of antihypertensive drugs before
intervention (week 4) were 2.8+0.6, 2.8+0.9 and 2.8+0.9
for groups A, B and C respectively. The mean number of
drugs after intervention significantly increased to 3.7+0.8
and 3.6+0.9 in groups B and C respectively.
Discussion
An overall result of this study was that the various maneu-
vers executed between the start and end of the study
resulted in the normalization of blood pressure in 53% of
the patients who had been persistently hypertensive by
OBP measurement despite treatment with multiple drugs.
The various maneuvers included: start of both home
blood pressure monitoring and drug regimen compliance
monitoring at week 0, exclusion of uncontrolled hyper-
tension caused by a white-coat effect, change of the drug
regimen in Groups B and C at week 4, and the commence-
ment of a compliance-enhancement program in Group C
at week 4. In the persistently hypertensive groups B and C,
39% achieved normalization of blood pressure. In the
present study, a number of factors made it impossible to
deduce which of the various maneuvers, including com-
pliance-improvement, played the dominant role in the
normalization of blood pressure, nor is it evident what
sorts of reductions in the number of drugs or doses pre-
scribed might be possible in correctly dosing former poor
compliers, without loss of control over blood pressure.
Observed Daily probability of intake after week 4 visit Figure 4
Observed Daily probability of intake after week 4 visit. The 
compliance after week 4 is not different in the three groups 
and stayed constant over time.
Table 3: Compliance summary statistics
Groups Week 0–4 (Adherence) Week 4–12 (Compliance)
Cod (*) Tac (*) Cod (*) Tac (*)
15 days preceding the Week 4 
visit
15 days preceding the Week 4 
visit
Between the first and last events 
occurring between weeks 4 and 
12
Between the first and last events 
occurring between weeks 4 and 
12
A Median 0.9667
Mean 0.8625
Median 1.0000
Mean 0.9563
Median 0.9652
Mean 0.9133
Median 1.0045
Mean 0.9775
B Median 0.9333
Mean 0.7770
Median 1.0000
Mean 0.9046
Median 0.9815
Mean 0.9281
Median 1.0000
Mean 0.9770
C Median 0.9333
Mean 0.7770
Median 1.0000
Mean 0.9046
Median 1.0000
Mean 0.9709
Median 1.0000
Mean 0.9973
(*) cod = correct dosing.
tac = taking compliance.
Observed Daily probability of intake preceding the week 4  visit Figure 3
Observed Daily probability of intake preceding the week 4 
visit. Difference between the adherence in the controlled 
patients and the non controlled patients: the adherence of 
non controlled patients was significant lower and the 
decrease steeper.
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A fortunate aspect of the present study is that the maneu-
vers performed were fairly simple and cost effective, and
without discernible hazards, so that repetition with better
collection of data and simplified designs may allow iden-
tification of the most important maneuvers.
Compliance in week 0–4 was monitored with up to 3
MEMS boxes in individual patients. Since – as in previous
studies – no difference could be observed between 1 or
more MEMS boxes, we decided to continue on 1 MEMS
box for Cande/TZD
During the run-in period, the percentage of prescribed
doses taken, which is one of several ways to express drug
regimen compliance, fluctuated to a slight extent, but
remained essentially constant in Group A. In contrast, the
patients who were destined to comprise Groups B and C
showed a more or less continuous decline in percentage of
prescribed doses taken, from the mid-point to the end of
the 4-week run-in period, during which time the mean
percentage of prescribed doses taken declined from 93%
to 62%.
Remarkably, compliance in Groups B and C improved
immediately following the visit at week 4 and continued,
as shown in Figure 4, to fluctuate from day to day in the
region between 85% and 100% of prescribed doses taken.
A possible explanation of this phenomena is the switch to
a more efficient therapy and a QD regimen.
A notable finding was a substantially higher incidence of
omitted doses on weekends (Fridays-Saturdays-Sundays)
than on weekdays (Mondays thru Thursdays). This phe-
nomenon was also reported in a previous work by Mal-
lion et al. [10]. This prominent effect does not show up in
Figure 4, as the data are plotted on an ordinal day basis,
rather than a calendar day basis – an object lesson in how
some methods of displaying averaged time-series data can
camouflage important features.
Following the change to candesartan/HCTZ in Groups
B&C significant BP reductions could be observed with all
three methods of BP monitoring. Since ABPM is more use-
ful than OBPM in stratifying cardiovascular risk in
patients with refractory hypertension, we used the nor-
malization criteria of ABPM. It is remarkable that a nor-
malization rate of 39% was achieved as monitored by
ABPM in groups B&C. This beneficial finding is in keeping
with results of prior studies, and may in part be due to the
relatively long duration of action of candesartan, which
could be expected to have the effect of allowing antihyper-
tensive action to persist in the face of delayed or omitted
doses [11-14]. The better blood pressure control at week
12 may be explained by both improved compliance and
switch to Candesartan/TZD. However, our study design
did not allow to give a good estimate of the relative con-
tribution of each factor. But Burnier et al could demon-
trated in a prior study that monitoring of compliance
alone was associated with a significant improvement of
blood pressure at 2 months (systolic/diastolic blood pres-
sure:156/106 +/- 23/11 versus 145/97 +/- 20/15 mmHg,
P < 0.01) [15].
Drug regimen compliance after week 4 was not different
in the three groups, staying essentially constant over time,
very close to correct dosing each day, with of course the
exception of the 'weekend effect', the pressure correlates of
which we did not explore. Relatively long-acting antihy-
pertensive agents, e.g., candesartan, can 'forgive' dose
omissions occurring on weekends, whereas relatively
short-acting drugs, that cannot maintain pressure control
for at least 48 hrs after a last-taken dose, cannot [11].
Limitations of the study
Clearly the transactions between investigative staff and
patients had substantial though variably sustained
impact. We do not know – and it is an important omis-
sion that should be avoided in future studies – what the
dosing histories and thus the compliance levels were in
Table 4: Blood pressure values for all three methods of measurement after the run-in period (visit week 4).
Group A Week 4 Group B Week 4 Group C Week 4
BP method
OBPM syst 150 ± 17 # 162 ± 15 161 ± 16 n.s.
OBPM diast 88 ± 10 89 ± 13 88 ± 13 n.s.
SBPM syst 128 ± 5 # 155 ± 10 154 ± 12 n.s.
SBPM diast 79 ± 5 # 84 ± 12 84 ± 12 n.s.
ABPM syst 122 ± 6 # 149 ± 10 144 ± 11 n.s.
ABPM diast 74 ± 5 # 80 ± 12 78 ± 10 n.s.
OBPM: Office blood pressure measurement.
SBPM: Self blood pressure measurement.
ABPM: Ambulatory 24-h blood pressure measurement.
syst = systolic, diast = diastolic.
#: t-test p < 0.05/3 (Bonferroni's correction for multiple testing A vs B, A vs C and B vs C).
n.s. = B vs C.BMC Cardiovascular Disorders 2006, 6:36 http://www.biomedcentral.com/1471-2261/6/36
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the period prior to the start of the run-in period. One nat-
urally wonders if it were not generally poor in many or
most of the patients before the start of the study, where-
upon the first measurements showed it to be high in all
patients, perhaps a forerunner of the abrupt jump in com-
pliance that we see in Groups B and C immediately after
the week 4 visit. Perhaps – but we can only speculate and
take the point in designing future studies – the patients
who were to comprise Group A were, prior to the start of
the study, poorly compliant, but received enough motiva-
tion from the various maneuvers made at the start of the
study, so that their compliance rose and their blood pres-
sures concomitantly normalized, where they remained
throughout the 12-week study. A high priority, therefore,
is to master – as some investigators have [16,17] – the art
of introducing electronic monitoring in an unperturbing
manner, so that valid pre-study dosing histories can be
captured.
For reasons that this study does not reveal, the week 4 visit
restored average compliance in Groups B and C to the
same high range it had in the first 2 weeks after of the ini-
tial visit at the start of the study. One naturally wonders
whether maneuvers begun at the start of the study, 4
weeks previously, had not had a similar effect, akin to that
which we see after week 4, of improving a previously
unsatisfactory compliance. It is also a matter of conjecture
about which of the various maneuvers uniquely associ-
ated with the conduct of the study played the biggest role
in (a) achieving a sustained increase in compliance in
Groups B and C, and (b) achieving blood pressure control
in a fraction of the patients in Groups B and C.
Another limitation of the study was the rather short dura-
tion of the study. It is well known that long term, "real life
" compliance may not be reflected by short observation
periods 1 or 2 months.
Conclusion
This study demonstrated blood pressure normalization in
a 53% of previously uncontroled hypertensives. Clearly,
the use of ABPM and SBPM were helpful in identifying
white-coat effects. The mechanisms for this improvement
are not clear, but each of the maneuvers that preceded this
Change in blood pressure between visit week 4 and visit week 12 Figure 5
Change in blood pressure between visit week 4 and visit week 12. For 24-h-ABPM the respective values of the last day of run-
in and the last day of week 12 are compared. For SBPM the mean values 14 days preceding week 4 visit are compared with the 
14 days preceding week 12 visit are compared. White bars: change of systolic blood pressure value, black bars: change of 
diastolic blood pressure value. *: t-test p < 0.05. **:t-test p < 0,01.
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improvement are simple, safe, easily applied, and rela-
tively economical. Further work, taking cognizance of the
shortcomings of the present study, can probably differen-
tiate the more from the less effective of the maneuvers,
and help improve the proficiency of their use.
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